2018
Prior Medications and the Cardiovascular Benefits From Combination Angiotensin‐Converting Enzyme Inhibition Plus Calcium Channel Blockade Among High‐Risk Hypertensive Patients
Brook RD, Kaciroti N, Bakris G, Dahlöf B, Pitt B, Velazquez E, Weber M, Zappe DH, Hau T, Jamerson KA. Prior Medications and the Cardiovascular Benefits From Combination Angiotensin‐Converting Enzyme Inhibition Plus Calcium Channel Blockade Among High‐Risk Hypertensive Patients. Journal Of The American Heart Association 2018, 7: e006940. PMID: 29301757, PMCID: PMC5778960, DOI: 10.1161/jaha.117.006940.Peer-Reviewed Original ResearchMeSH KeywordsAgedAmlodipineAngiotensin-Converting Enzyme InhibitorsAntihypertensive AgentsBenzazepinesBlood PressureCalcium Channel BlockersCause of DeathDrug Therapy, CombinationFemaleHumansHydrochlorothiazideHypertensionMaleMiddle AgedRandomized Controlled Trials as TopicRisk AssessmentRisk FactorsSodium Chloride Symporter InhibitorsTime FactorsTreatment OutcomeConceptsHigh-risk hypertensive patientsCardiovascular risk reductionHypertensive patientsAntihypertensive regimenCombination therapyBlood pressure control statusGreater cardiovascular risk reductionRenin-angiotensin system blockadeAngiotensin-converting enzyme inhibitorPrimary composite eventsPrior antihypertensive therapyPrimary composite outcomeCalcium channel blockadeLipid-lowering medicationsPrior medication useCalcium channel blockersRisk reductionACCOMPLISH trialAntihypertensive therapySystem blockadeCardiovascular benefitsCombination regimenComposite outcomeDrug regimensMedication use
2016
Effect of single and dual renin-angiotensin blockade on stroke in patients with and without diabetes in VALIANT
Abdul-Rahim AH, Docherty KF, Skali H, Køber L, Dickstein K, Maggioni AP, Mareev V, Zannad F, Velazquez EJ, Califf RM, Pfeffer MA, Solomon SD, Lees KR, McMurray JJ. Effect of single and dual renin-angiotensin blockade on stroke in patients with and without diabetes in VALIANT. European Stroke Journal 2016, 1: 93-100. PMID: 31008270, PMCID: PMC6301225, DOI: 10.1177/2396987316646025.Peer-Reviewed Original ResearchAngiotensin receptor blockersRisk of strokeAcute myocardial infarctionMyocardial infarctionReceptor blockersDual renin-angiotensin system blockadeEnzyme inhibitorsDual renin-angiotensin blockadeRenin-angiotensin system blockadeAcute Myocardial Infarction trialCox proportional hazards regressionRenin-angiotensin blockadeMyocardial Infarction trialRate of strokeVentricular systolic dysfunctionProportional hazards regressionRenin inhibitor aliskirenSystem blockadeSystolic dysfunctionHazard ratioHeart failureTreatment groupsPatientsDiabetesStroke
2003
VALsartan In Acute myocardial iNfarcTion (VALIANT) trial: baseline characteristics in context
Velazquez EJ, Pfeffer MA, McMurray JV, Maggioni AP, Rouleau J, Van de Werf F, Kober L, White HD, Swedberg K, Leimberger JD, Gallo P, Sellers MA, Edwards S, Henis M, Califf RM, Investigators F. VALsartan In Acute myocardial iNfarcTion (VALIANT) trial: baseline characteristics in context. European Journal Of Heart Failure 2003, 5: 537-544. PMID: 12921816, DOI: 10.1016/s1388-9842(03)00112-0.Peer-Reviewed Original ResearchMeSH KeywordsAgedAngiotensin Receptor AntagonistsCaptoprilDouble-Blind MethodFemaleGlyceraldehyde-3-Phosphate DehydrogenasesHeart FailureHumansMaleMiddle AgedMulticenter Studies as TopicMyocardial InfarctionPeptide FragmentsRandomized Controlled Trials as TopicTetrazolesValineValsartanVentricular Dysfunction, LeftConceptsAcute Myocardial Infarction trialAngiotensin receptor blockadeMyocardial Infarction trialHeart failureMyocardial infarctionACEI trialsRenin-angiotensin system blockadePlacebo-controlled trialVentricular systolic dysfunctionActive-controlled trialEvidence-based careHigh-risk populationEvidence-based therapiesCardiovascular outcomesSystem blockadeSystolic dysfunctionBaseline characteristicsStandard treatmentRepresentative cohortPatientsMI trialsTrialsValsartanACEIsLVSD